Country for PR: United Kingdom
Contributor: PR Newswire Europe
Wednesday, May 26 2021 - 00:27
AsiaNet
OptraSCAN Announces CytoSiA – A Complete Digital Solution For Scanning And Analysis Of Cytology Slides At Affordable Pricing
SAN JOSE, Calif. and PUNE, India, May 25, 2021 /PRNewswire-AsiaNet/ --

- OptraSCAN's Intelligent Tool CytoSiA – To Advance Cytology Screening Through 
Unmatched Image Quality And Artificial Intelligence Based Image Analysis 
Solution


    OptraSCAN® [https://www.optrascan.com/], the leading On-Demand Digital 
Pathology solution provider, today announced its intelligent solution CytoSiA 
(https://www.optrascan.com/solutions/cytology-analysis) for rapid yet 
affordable scanning and analyzing of liquid-based cytology slides and 
pap-smears. It is a complete solution consisting of OptraSCAN's digital 
pathology scanner, storage, and powerful artificial intelligence (AI) 
algorithms to assist pathologists and cytotechnologists in screening and 
detection of cervical cancer, pre-cancerous lesions, atypical cells, and all 
other cytologic categories. Multiple hospitals and pathology laboratories 
globally have already installed CytoSiA and are witnessing improved patient 
outcomes, increased efficiency, and productivity needed to cope with the 
ever-increasing demand of cytology cases. 

    "OptraSCAN is redefining cervical cancer screening by introducing CytoSiA, 
[https://www.optrascan.com/solutions/cytology-analysis] it offers a plethora of 
features, to effectively screen liquid-based cytology slides, and pap smears to 
differentiate between normal and abnormal cervical cells using Bethesda 
classifications on normal to squamous cell carcinoma (NILM/LSIL/HSIL/SCC)", 
said Abhi Gholap, [https://www.optrascan.com/about-us/leadership-team] Founder 
of OptraSCAN. With a range of scanning devices handling as low as 50 slides a 
week to 5000 slides a week at an extremely affordable price," he further added.
OptraSCANS's digital scanners can scan cytology slides of size 15x15 mm area at 
40x magnification in less than 60 seconds while generating the highest quality 
image. CytoSia incorporates patented technology- composite imaging 
(https://www.optrascan.com/news/140-optrascan-to-expand-into-digital-cytology-so
lution) which finds all pixels in focus from various Z plane images and 
stitches back to create a single layer composite image. This composite imaging 
technology is considerably efficient as compared to traditional Z-Stacking 
Technology. It allows for rapid and precise screening of the entire slide 
within seconds. This level of precision and quality is imperative for analyzing 
the samples. Furthermore, it presents to the screener images of fields that 
would be essential in providing a cytological interpretation, place them into 
categories, and filter out the redundancies.

    CytoSiA [https://www.optrascan.com/solutions/cytology-analysis] when used 
as a companion diagnostic tool, it notifies pathologists when inconsistencies 
between their interpretation and the AI algorithm's findings are observed, 
offering a safeguard against error or misinterpretation, while also improving 
overall care quality.

    Features of CytoSiA:
- Automated computation of sample adequacy for the whole slide cytology image 
- Identification of abnormal cells and other entities based on morphological 
features and AI-based classification using Bethesda scoring 
- Identification of reactive, endometrial, actinomyces, candida, clue cells, 
trichomonas vaginalis, and herpes entities 
- Identification of entities including blood, inflammation, and lubricant

    "AI-based image analysis requires images that are of superior quality," 
said Dr Aparna Joshi, Medical Director, at OptraSCAN. "Our team has developed 
an intelligent imaging technology that transforms physical glass cytology 
slides into digital images with exceptional clarity. Advanced image analysis 
and standardization are now achievable with this quality of digitization," she 
further added. 

    Contact OptraSCAN [info@optrascan.com] 

    About OptraSCAN, Inc:

    OptraSCAN® are pioneers in the On-Demand Digital Pathology® System, focused 
on delivering fully integrated, affordable solutions that will maximize your 
return on investment and improve the performance of your pathology services. An 
ISO 13485 certified company and CE marked whole slide scanners for IVD use, 
OptraSCAN is working to eliminate the barriers to "Go Digital" no matter the 
size of the pathology lab, the lab's throughput or global location.

    OptraSCAN's end-to-end digital pathology solution provides effective 
acquisition of whole slide images, viewing, storing, real-time sharing, 
reporting and AI & ML based Image analysis solutions via On-Demand or outright 
purchase model. Follow Us on LinkedIn 
[https://in.linkedin.com/company/optra-scan] and Twitter 
[https://mobile.twitter.com/optrascan].

    Media Inquiries Contact:

    Anjana Athanikar
    Manager – Marketing Communications  
    a.athanikar@optraventures.com

    Logo: https://mma.prnewswire.com/media/1517923/Optra_Scan_Logo.jpg  
    Photo: https://mma.prnewswire.com/media/1517924/OptraScan_CytoSiA.jpg 

    Source: OptraSCAN Inc.
Translations

Japanese